Evidence map›Paper›PMID 39484531›Full record

ArticlebioRxiv : the preprint server for biology2024

Site of breast cancer metastasis is independent of single nutrient levels.

Keene L Abbott, Sonu Subudhi, Raphael Ferreira, Yetiş Gültekin, Sophie C Steinbuch, Muhammad Bin Munim, Sophie E Honeder, Ashwin S Kumar, Diya L Ramesh, Michelle Wu and 19 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Keene L AbbottDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6166-704X
Sonu SubudhiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-5937-1880
Raphael FerreiraBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Yetiş GültekinDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sophie C SteinbuchSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Muhammad Bin MunimDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sophie E HonederKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ashwin S KumarBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Diya L RameshDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Michelle WuDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jacob A HansenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sharanya SivanandDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-2559-9270
Lisa M RiedmayrHarvard Medical School, Department of Genetics, Boston, MA, USA.
Mark DuquetteSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Ahmed AliDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nicole HenningKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Anna Shevzov-ZebrunDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Florian GourgueDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Anna M BarbeauDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Millenia WaiteWhitehead Institute for Biomedical Research, Cambridge, MA, USA.
Tenzin KunchokWhitehead Institute for Biomedical Research, Cambridge, MA, USA.
Gino B FerraroSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Brian T DoDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Virginia SpanoudakiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Francisco J Sánchez-RiveraDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Xin JinWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang Province, China.
George M ChurchHarvard Medical School, Department of Genetics, Boston, MA, USA.
Rakesh K JainSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Matthew G Vander HeidenDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6702-4192

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3M
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2M
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2R01NS118929 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2021 to 2025
$2.0M
Exploiting metabolic vulnerabilities of breast cancer brain metastases for therapyF31CA271787 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABBOTT, KEENE · 2022 to 2023
$94k
NCI NIH HHS F31 CA271787NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA259253NCI NIH HHS R35 CA242379NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842NIGMS NIH HHS T32 GM007287NINDS NIH HHS R01 NS118929
6 · The paper itself

Abstract

Cancer metastasis is a major contributor to patient morbidity and mortality

Identifiers

PMID39484531
PMCPMC11527034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.